Alnylam Pharmaceuticals
ALNY
#640
Rank
$39.47 B
Marketcap
$295.63
Share price
-2.10%
Change (1 day)
-3.42%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of June 2026 (TTM): 9.21

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 50.0. At the end of 2026 the company had a P/S ratio of 9.82.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20269.82-31.03%
202514.24.27%
202413.73.91%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Novartis
NVS
4.91-46.64%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
1.85-79.86%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
4.22-54.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.8458-90.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
1.65-82.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
2.33-74.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
9.71 5.45%๐Ÿ‡บ๐Ÿ‡ธ USA